Status:
COMPLETED
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic sy...
Detailed Description
We hypothesize that acipimox, by decreasing plasma FFA concentrations, will augment endothelium-dependent vasodilation in conduit vessels and insulin-mediated vasodilation in forearm resistance arteri...
Eligibility Criteria
Inclusion
- Adults with metabolic syndrome, defined as the presence of 3 of 5 components of the syndrome as defined by the National Cholesterol Education Program including:
- abdominal obesity
- elevated fasting blood sugar (110 mg/dL\< glucose \< 126 mg/dL)
- low HDL
- elevated fasting blood triglycerides (\> 150 mg/dL)
- hypertension (BP \> 140/90 mm HG)
- Normal cardiovascular examination
Exclusion
- Diabetes mellitus
- Untreated hypercholesterolemia (LDL \> 75th percentile for age)
- Cigarette smoking within 1 year
- Renal insufficiency (creatinine \> 1.4 mg/dl)
- Blood dyscrasia
- Hepatic dysfunction (ALT \> 2x normal)
- Evident coronary/peripheral atherosclerosis
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00759291
Start Date
April 1 2006
End Date
December 30 2017
Last Update
February 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115